Physician profile
Michael E Schwartz
NPI 1700847514
$1,155.88
in general payments reported to CMS, 2019-2025
20 companies · $288 in 2025
The $288 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.99 · 2020: $244 · 2021: $333 · 2022: $97.34 · 2023: $149 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $437.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $463.53 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $125.01 | 2023 | Xarelto |
| Redhill Biopharma INC. | $71.67 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.23 | 2021-2025 | Entyvio |
| Neuraxis, INC. | $58.50 | 2025 | |
| Gilead Sciences, INC. | $49.72 | 2021-2022 | |
| Braintree Laboratories, INC. | $38.83 | 2025 | Suflave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.43 | 2020-2025 | Relistor, Trulance |
| Celltrion USA INC. | $30.43 | 2025 | Vegzelma |
| Siemens Medical Solutions USA, INC. | $25.07 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $24.17 | 2023 | Dupixent |
| Shield Therapeutics INC | $21.04 | 2025 | |
| Echosens North America, INC. | $21.01 | 2025 | Fibroscan |
| Boston Scientific Corporation | $20.57 | 2022 | |
| Aimmune Therapeutics, INC. | $20.52 | 2025 | Zenpep |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $19.92 | 2019 | |
| Novo Nordisk INC | $18.91 | 2025 | Wegovy |
| Ucb, INC. | $17.73 | 2020 | |
| Intercept Pharmaceuticals, INC. | $13.92 | 2020 | |
| Phathom Pharmaceuticals, INC. | $13.67 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.